Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

MLA

Cholujova, Danka, et al. “Realgar Nanoparticles versus ATO Arsenic Compounds Induce in Vitro and in Vivo Activity against Multiple Myeloma.” British Journal of Haematology, vol. 179, no. 5, Dec. 2017, pp. 756–71. EBSCOhost, https://doi.org/10.1111/bjh.14974.

APA

Cholujova, D., Bujnakova, Z., Dutkova, E., Hideshima, T., Groen, R. W., Mitsiades, C. S., Richardson, P. G., Dorfman, D. M., Balaz, P., Anderson, K. C., & Jakubikova, J. (2017). Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. British Journal of Haematology, 179(5), 756–771. https://doi.org/10.1111/bjh.14974

Chicago

Cholujova, Danka, Zdenka Bujnakova, Erika Dutkova, Teru Hideshima, Richard W. Groen, Constantine S. Mitsiades, Paul G. Richardson, et al. 2017. “Realgar Nanoparticles versus ATO Arsenic Compounds Induce in Vitro and in Vivo Activity against Multiple Myeloma.” British Journal of Haematology 179 (5): 756–71. doi:10.1111/bjh.14974.